2015-11-20
Kancera provides operational update
Kancera hereby provides an operational update on the PFKFB3 and HDAC6 projects as well as the EU-funded epigenetically targeted parasitic project A-PARADDISE.
Read More
2015-10-01
Kancera provides operational update on the ROR and Fractalkine projects
In connection with a meeting arranged by the Swedish Shareholders' Association in Malmö on September 30, Kancera provides an operational update on the ROR and Fractalkine projects.
Read More
2015-09-08
Kancera evaluates immuno-oncology drug candidate
Kancera has entered into an agreement with Acturum Life Science AB in order to evaluate and further develop the unique Fractalkine inhibitor AZD8797. Published research points to that Fractalkine signaling probably contributes to the growth and spread of tumors...
Read More
2015-05-05
Kancera provides operational update on the cancer projects
Kancera reports results from the company's cancer project portfolio generated in 2015.
Read More
2015-02-03
Kancera provides operational update on the ROR project
Kancera reports that a second efficacy study of the drug candidate KAN0439834 (small molecule inhibitor of ROR1) has been completed in an animal model of an advanced stage of chronic lymphocytic leukemia. The results show that KAN0439834 reduces the...
Read More
2014-12-10
Kancera provides operational update on the HDAC6 project
Kancera reports that an investigation of the mechanism of action of the company's patent-pending HDAC6 inhibitors has demonstrated a unique profile that could strengthen the competitiveness of the project.
Read More
2014-11-03
Kancera selects a first candidate drug in the ROR project
Kancera reports the results of an analysis of the preclinical efficacy study that was completed during the third quarter as reported in a press release on October 3, 2014. The results confirm that the number of cancer cells in...
Read More
2014-10-03
Kancera provides operational update on the ROR project
Kancera reports that an initial efficacy study of KAN0439834 (a small molecule inhibitor of ROR1) has been completed in an animal model of chronic lymphocytic leukemia. Preliminary results show that KAN0439834 reduces the number of ROR-expressing leukemia cells after...
Read More
2014-09-17
Kancera provides new information on the ROR project in connection with the “U.S. Cancer Immunotherapy Partnering Mission”
In connection with presentations for pharmaceutical companies and universities during the "U.S. Cancer Immunotherapy Partnering Mission" (CIPM), 15 -19 September 2014, Kancera communicates new information regarding the company's ROR1-directed small molecules and vaccine candidates. This information concerns the efficacy...
Read More
2014-05-14
Kancera AB files patent for HDAC6 inhibitors against cancer
Kancera reports that the company has registered a patent application (EP14167988.6) for new compounds against cancer that selectively inhibit the enzyme HDAC6. The new patent application is based on the ability of HDAC6 inhibitors to influence mechanisms both inside...
Read More